OmnigenicsAI, a precision medicine company, agreed to go public via SPAC merger with APx Acquisition, a publicly traded special purpose acquisition company, in a $340m deal. "OmnigenicsAI is pioneering a new category of healthcare that integrates the groundbreaking potential of artificial intelligence with today´s access to vast amounts of genomic data, to provide personalized insights that empower individuals to make informed health decisions throughout their lives," Mark Ramondt, OmnigenicsAI CEO.